Day: March 13, 2024

PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®

Written by Customer Service on March 13, 2024. Posted in Public Companies.

Preclinical research published in Vaccines demonstrates Infectimune® significantly improved quantity and quality of potent multifunctional CD4 T cells compared to vaccine adjuvants Patent for composition of matter and use of Infectimune® based influenza vaccines granted in the United States PRINCETON, N.J., March 13, 2024 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or “the Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell-activating platforms, today announced the publication of preclinical research and a patent granted by the United States Patent and Trademark Office (USPTO) that strengthen the foundation of the Company’s infectious disease vaccine platform...

HealthLynked Welcomes David Rosal as New Chief Financial Officer

Written by Customer Service on March 13, 2024. Posted in Public Companies.

NAPLES, Fla., March 13, 2024 (GLOBE NEWSWIRE) — via IBN — HealthLynked Corp. (OTCQB: HLYK), a pioneering provider of healthcare network and services, is delighted to announce the appointment of David Rosal as its new Chief Financial Officer (CFO), effective March 18, 2024. With a distinguished career that spans over two decades, Rosal brings a wealth of experience in financial planning, business scaling, and strategic development, notably from his impactful roles at McDonald’s Corporation and Teradata. During his tenure at McDonald’s, Rosal was instrumental in scaling the business through his expertise in financial planning and analysis, business integration, concept development, and due diligence for M&A of major businesses. His leadership significantly contributed to the company’s growth and operational...

Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA

Written by Customer Service on March 13, 2024. Posted in Public Companies.

BOSTON, March 13, 2024 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Santhosh Palani, Ph.D., CFA, to its board of directors, effective March 12, 2024. “We are thrilled to have Santhosh join the Pyxis Oncology board. Santhosh brings a wealth of business, investment, strategic, and board experience to our team,” said Lara S. Sullivan, M.D., President and Chief Executive Officer of Pyxis Oncology. “Santhosh’s guidance, drawing from his experience working across the biopharma industry, will be invaluable as we continue clinical development of our lead asset, PYX-201, a first-in-class and first-in-concept tumor stroma targeting ADC against EDB-fibronectin. His background is...

AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease

Written by Customer Service on March 13, 2024. Posted in Public Companies.

PRESS RELEASE NEW RESEARCH SHOWS THAT MASITINIB LIMITS NEURONAL DAMAGE IN A MODEL OF NEUROIMMUNE-DRIVEN NEURODEGENERATIVE DISEASE THIS IS THE FIRST DEMONSTRATION THAT MASITINIB CAN LOWER SERUM NEUROFILAMENT LIGHT CHAIN, AN IMPORTANT BIOMARKER FOR NEURODEGENERATIVE DISORDERS Paris, March 13, 2024, 12.45pm CET AB Science SA (Euronext – FR0010557264 – AB) today announced the publication of new preclinical results for masitinib in neurodegenerative diseases (NDD). Findings have been published on the bioRxiv preprint service as an article entitled, ‘Masitinib limits neuronal damage, as measured by serum neurofilament light chain concentration, in a model of neuroimmune-driven neurodegenerative disease’. This article is freely accessible online from the bioRxiv site [1]. The neuroprotective action of masitinib was studied in an...

Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)

Written by Customer Service on March 13, 2024. Posted in Public Companies.

AGAMREE® (vamorolone) a Novel Alternative Corticosteroid with Demonstrated Properties in Maintaining Efficacy and a Well-Tolerated Side Effect Profile Available in the U.S. by Prescription for Patients Aged Two Years and Older Catalyst Pathways® Program will Support AGAMREE Patients and Available to Help Ensure DMD Patients Affordable Access and Product Education CORAL GABLES, Fla., March 13, 2024 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company, today announced the U.S. commercial launch of AGAMREE® (vamorolone) oral suspension 40 mg/mL for the treatment of Duchenne Muscular Dystrophy (“DMD”) in patients aged two years and older. Following the U.S. Food and Drug Administration (“FDA”) approval on October 26, 2023, AGAMREE...

Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results

Written by Customer Service on March 13, 2024. Posted in Earnings Releases And Operating Results.

— Company ends 2023 with approximately $123.6 million in cash and investments. Combined with gross proceeds from $108.9 million private placement in January, Solid has anticipated cash runway into 2026 — — FDA cleared IND and granted Fast Track Designation and Orphan Drug Designation for Duchenne muscular dystrophy (Duchenne) gene therapy candidate SGT-003 with patient dosing in Phase 1/2 trial expected Q2 2024 — — Company entered into non-exclusive licensing agreement for use of its proprietary, muscle-targeted AAV-SLB101 capsid — CHARLESTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided...

AYR Wellness Reports Fourth Quarter and Full Year 2023 Results

Written by Customer Service on March 13, 2024. Posted in Earnings Releases And Operating Results.

FY 2023 Revenue up 10% to $463.6 Million, Excluding Discontinued Operations FY 2023 GAAP Loss from Operations Improved to $37.2 Million, Excluding Discontinued Operations FY 2023 Adjusted EBITDA1 up 51% to $114.0 Million, with Adjusted EBITDA Margin of 25% Completed Plan of Arrangement Transactions, Including Extending the Maturity of all of its Senior Notes and Certain Other Debt by Two Years, in February 2024 MIAMI, March 13, 2024 (GLOBE NEWSWIRE) — AYR Wellness Inc. (CSE: AYR.A, OTCQX: AYRWF) (“AYR” or the “Company”), a leading vertically integrated U.S. multi-state cannabis operator, is reporting financial results for the fourth quarter and full year ended December 31, 2023. Unless otherwise noted, all results are presented in U.S. dollars. David Goubert, President & CEO of AYR, said, “2023 was a transformational year...

GURU Organic Energy Unveils New Website and New Revitalized Brand Design

Written by Customer Service on March 13, 2024. Posted in Public Companies.

GURU Organic EnergyGURU’s new websiteStrategic investment reflects GURU’s growing market share in its online growth vector. Redesigned website elevates the GURU shopping experience and supports evolving consumer needs. Website also showcases GURU’s upcoming new can design, with a dazzling new look and greater emphasis on the brand’s energy attributes.MONTREAL, March 13, 2024 (GLOBE NEWSWIRE) — GURU Organic Energy Corp. (TSX: GURU) (“GURU” or the “Company”), Canada’s leading organic energy drink brand1, is excited to announce the launch of its redesigned website featuring a sleeker interface, simplified navigation, and an overall enhanced user experience. This includes an improved subscription program that offers more choices to consumers and is easier to navigate and customize. The website also showcases GURU’s...

TILT Holdings Announces New Brand Partnership with LEVEL to Bring Their Cannabis Tablets to Pennsylvania

Written by Customer Service on March 13, 2024. Posted in Public Companies.

Level’s Tablets to Launch in The Coming Weeks PHOENIX, March 13, 2024 (GLOBE NEWSWIRE) — TILT Holdings Inc. (“TILT” or the “Company”) (NEO: TILT) (OTCQB: TLLTF), a global provider of cannabis business solutions including inhalation technologies, cultivation, manufacturing, processing, brand development and retail, today announced a new brand partnership to distribute LEVEL’s targeted, effects-based infused tablets to patients in Pennsylvania. “Partnering with LEVEL to bring their products to market in Pennsylvania expands TILT’s offerings in a meaningful way for medical patients. We love that these oral tablets are portable, discreet, and allow for dialed-in dosing.” said Tim Conder, Chief Executive Officer of TILT. “This collaboration underscores our commitment to innovation. Together, TILT and LEVEL are opening doors to forge...

Agrify Corporation Announces Turnkey Extraction Equipment Deal with Multi-State Operator Justice Cannabis Co. Expanding into New Jersey Market

Written by Customer Service on March 13, 2024. Posted in Public Companies.

TROY, Mich., March 13, 2024 (GLOBE NEWSWIRE) — Agrify Corporation (Nasdaq: AGFY) (“Agrify” or the “Company”), a leading provider of innovative cultivation and extraction solutions for the cannabis industry, today announced the signing of a Turnkey Hydrocarbon Extraction and Lab Equipment Package with Justice Cannabis Co. (“Justice Cannabis” or the “Customer”), a licensed multi-state operator with 14 dispensaries around the Country now expanding into the New Jersey market. Justice Cannabis has purchased Agrify’s Turnkey Hydrocarbon Extraction and Lab Equipment Package, which includes a X10 Hydrocarbon Extractor, Filtration Equipment, a Solvent Recovery System, a 20L Decarboxylation Package, a Diamond-Miner, and a Thin-Film Distillation System. In addition, Justice Cannabis has also purchased Agrify’s UL-Compliant C1D1 Explosion...

Day: March 13, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice